Results 201 to 210 of about 77,108 (288)

Nivolumab and Ipilimumab in Advanced Mismatch Repair-Deficient/Microsatellite Instability-High Noncolorectal Cancers: A Nonrandomized Clinical Trial. [PDF]

JAMA Oncol
Carlino MS, Gao B, Michael M, Marshall H, Gunjur A, Chan H, Zielinski R, So J, Harris SJ, Kee D, Collins IM, Lam WS, Lyle M, Underhill C, Brown MP, Harrup R, Wong SF, Grady J, Ballinger M, Tavancheh E, Thomas DM, Palmer J, Wilkie K, Cebon J, Klein O.   +24 more
europepmc   +1 more source

Albumin Levels Are Predictive of Cachexia‐Induced Time‐Dependent Clearance of Therapeutic Antibodies: A Physiologically Based Pharmacokinetic Model of Durvalumab

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Cachexia is a metabolic condition that accelerates the clearance of monoclonal antibodies in cancer patients and is a known mechanism causing time‐dependent clearance. Successful anticancer treatment often ameliorates symptoms of cachexia, reducing the drug clearance over time especially in patients who respond. Serum albumin level is a common
Jeffrey R. Proctor, Harvey Wong
wiley   +1 more source

Very Late Recurrence of Clear Cell Renal Cell Carcinoma With Pancreatic and Hepatic Metastases Showing Durable Response to Dual Checkpoint Blockade. [PDF]

Clin Case Rep
Ito F, Kobayashi K, Hayashi G, Kamijo S, Fujita T.   +4 more
europepmc   +1 more source

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 3, Page 383-395, February 2026.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

Checkpoint Inhibitors and Beyond: A Systematic Review of Immunotherapy in Cutaneous Malignancies. [PDF]

Cureus
Rashid Y, Devi S K, Gonzalez-Espinosa TF, Jain J, Dalain M, Baig R, D'Amico GA, Mowo-Wale AG, Khomchenko M, Baby N, Yateem D, Duhamel A, Ali R.   +12 more
europepmc   +1 more source

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Annals of Oncology, 2017
N. Chaput, P. Lepage, C. Coutzac, E. Soularue, K. L. Roux, C. Monot, L. Boselli, É. Routier, L. Cassard, M. Collins, T. Vaysse, L. Marthey, A. Eggermont, V. Asvatourian, E. Lanoy, C. Mateus, C. Robert, F. Carbonnel   +17 more
semanticscholar   +1 more source

Efficacy and Safety of Hypofractionated Radiation Therapy Combined With Immunotherapy for Hepatocellular Carcinoma With Vp4 Portal Vein Tumor Thrombosis

Hepatology Research, Volume 56, Issue 2, Page 246-252, February 2026.
ABSTRACT Background Hepatocellular carcinoma (HCC) with Vp4 portal vein tumor thrombosis (PVTT) has an extremely poor prognosis, and evidence for effective systemic therapy is limited. Preclinical studies suggest that hypofractionated radiation therapy (HFRT) may enhance immune checkpoint inhibitor (ICI) efficacy through immunogenic cell death and ...
Masahiko Tameda, Hideaki Tanaka, Yutaka Toyomasu, Mizuki Kawachi, Hirono Owa, Mone Tsukimoto, Yasuyuki Tamai, Naoto Fujiwara, Ryuta Shigefuku, Suguru Ogura, Yoshihito Nomoto, Hayato Nakagawa   +11 more
wiley   +1 more source

Fatal hemoptysis despite complete remission of squamous cell carcinoma after chemoradiotherapy followed by combined ipilimumab and nivolumab: An autopsy case report. [PDF]

Medicine (Baltimore)
Horie K, Nakayama S, Hoshino A, Okada M, Terai H, Suzuki Y, Asakura T.   +6 more
europepmc   +1 more source

T Cell Exhaustion in Hepatocellular Carcinoma: A Substantial Barrier in Immunotherapy

Journal of Cellular and Molecular Medicine, Volume 30, Issue 3, February 2026.
ABSTRACT Hepatocellular carcinoma (HCC), accounting for over 90% of primary liver cancers, remains a major global challenge for healthcare professionals. While immunotherapy has transformed the landscape of cancer treatment, its success is often limited by immune resistance, particularly through T cell exhaustion which remains a major barrier to ...
Kosar Nouri, Negar Asadollahei, Yasamin Haghir‐Sharif‐Zamini, Homeyra Seydi, Mahsa Salehi, Mehrnaz Mesdaghi, Mustapha Najimi, Massoud Vosough   +7 more
wiley   +1 more source

Successful Treatment of Nivolumab Plus Ipilimumab After Progression on Durvalumab Plus Tremelimumab in Advanced Hepatocellular Carcinoma: A Case Report. [PDF]

Cureus
Sasaki A, Kimura R, Okamoto R.
europepmc   +1 more source